Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models

Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models

Intraperitoneal (IP) chemotherapy for ovarian cancer treatment prolongs overall survival by 16 months compared to intravenous chemotherapy but is not widely practiced due to catheter-related complications and complexity of administration. An implantable, nonresorbable IP microdevice was used to rele...

Full description

Bibliographic Details
Main Authors: Na, Young Jeong, Fulci, Giulia, del Carmen, Marcela G., Birrer, Michael J., Ye, Hongye, Tanenbaum, Laura Melanie, Mantzavinou, Aikaterini, Cima, Michael J.
Other Authors: Harvard University--MIT Division of Health Sciences and Technology
Format: Article
Language:en_US
Published: Elsevier 2017
Online Access:http://hdl.handle.net/1721.1/106467
https://orcid.org/0000-0001-8586-6900
https://orcid.org/0000-0003-2379-6139

Internet

http://hdl.handle.net/1721.1/106467
https://orcid.org/0000-0001-8586-6900
https://orcid.org/0000-0003-2379-6139

Similar Items